156 related articles for article (PubMed ID: 17432099)
1. The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients.
Prasad R; Ibanez D; Gladman D; Urowitz M
Lupus; 2007; 16(3):157-62. PubMed ID: 17432099
[TBL] [Abstract][Full Text] [Related]
2. Development of new osteonecrosis in systemic lupus erythematosus patients in association with long-term corticosteroid therapy after disease recurrence.
Nakamura J; Ohtori S; Sakamoto M; Chuma A; Abe I; Shimizu K
Clin Exp Rheumatol; 2010; 28(1):13-8. PubMed ID: 20346232
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of cumulative corticosteroid dose and immunosuppressants on avascular necrosis in patients with systemic lupus erythematosus.
Kwon HH; Bang SY; Won S; Park Y; Yi JH; Joo YB; Lee HS; Bae SC
Lupus; 2018 Sep; 27(10):1644-1651. PubMed ID: 29950160
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors for Symptomatic Avascular Necrosis in Childhood-onset Systemic Lupus Erythematosus.
Yang Y; Kumar S; Lim LS; Silverman ED; Levy DM
J Rheumatol; 2015 Dec; 42(12):2304-9. PubMed ID: 26568601
[TBL] [Abstract][Full Text] [Related]
5. Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies.
Migliaresi S; Picillo U; Ambrosone L; Di Palma G; Mallozzi M; Tesone ER; Tirri G
Lupus; 1994 Feb; 3(1):37-41. PubMed ID: 8025584
[TBL] [Abstract][Full Text] [Related]
6. Non-corticosteroid risk factors of symptomatic avascular necrosis of bone in systemic lupus erythematosus: A retrospective case-control study.
Faezi ST; Hoseinian AS; Paragomi P; Akbarian M; Esfahanian F; Gharibdoost F; Akhlaghi M; Nadji A; Jamshidi AR; Shahram F; Nejadhosseinian M; Davatchi F
Mod Rheumatol; 2015 Jul; 25(4):590-4. PubMed ID: 25528860
[TBL] [Abstract][Full Text] [Related]
7. Damage in systemic lupus erythematosus and its association with corticosteroids.
Zonana-Nacach A; Barr SG; Magder LS; Petri M
Arthritis Rheum; 2000 Aug; 43(8):1801-8. PubMed ID: 10943870
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review and Metaanalysis.
Hussein S; Suitner M; Béland-Bonenfant S; Baril-Dionne A; Vandermeer B; Santesso N; Keeling S; Pope JE; Fifi-Mah A; Bourré-Tessier J
J Rheumatol; 2018 Oct; 45(10):1462-1476. PubMed ID: 29961688
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus.
Gladman DD; Urowitz MB; Chaudhry-Ahluwalia V; Hallet DC; Cook RJ
J Rheumatol; 2001 Apr; 28(4):761-5. PubMed ID: 11327247
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous repair of asymptomatic osteonecrosis associated with corticosteroid therapy in systemic lupus erythematosus: 10-year minimum follow-up with MRI.
Nakamura J; Harada Y; Oinuma K; Iida S; Kishida S; Takahashi K
Lupus; 2010 Oct; 19(11):1307-14. PubMed ID: 20605878
[TBL] [Abstract][Full Text] [Related]
11. [Avascular (aseptic) bone necrosis in SLE and nephrotic syndrome following corticosteroid therapy (author's transl)].
Inage H; Koyama A; Narita M; Tojo S; Iesato K; Takei I; Wakasin Y; Wakasin M
Nihon Jinzo Gakkai Shi; 1980 Apr; 22(4):393-9. PubMed ID: 7401392
[No Abstract] [Full Text] [Related]
12. Age at time of corticosteroid administration is a risk factor for osteonecrosis in pediatric patients with systemic lupus erythematosus: a prospective magnetic resonance imaging study.
Nakamura J; Saisu T; Yamashita K; Suzuki C; Kamegaya M; Takahashi K
Arthritis Rheum; 2010 Feb; 62(2):609-15. PubMed ID: 20112393
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort.
Yang SC; Lai YY; Huang MC; Tsai CS; Wang JL
Lupus; 2018 Oct; 27(11):1819-1827. PubMed ID: 30103646
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroids and low bone mineral density affect hip cartilage in systemic lupus erythematosus patients: Quantitative T2 mapping.
Hagiwara S; Nakamura J; Watanabe A; Kishida S; Ohtori S; Omae T; Miyamoto S; Orita S; Takahashi K
J Magn Reson Imaging; 2015 Dec; 42(6):1524-31. PubMed ID: 26019059
[TBL] [Abstract][Full Text] [Related]
15. Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation?
Rascu A; Manger K; Kraetsch HG; Kalden JR; Manger B
Lupus; 1996 Aug; 5(4):323-7. PubMed ID: 8869906
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus.
Compeyrot-Lacassagne S; Tyrrell PN; Atenafu E; Doria AS; Stephens D; Gilday D; Silverman ED
Arthritis Rheum; 2007 Jun; 56(6):1966-73. PubMed ID: 17530722
[TBL] [Abstract][Full Text] [Related]
17. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study.
Calvo-Alén J; McGwin G; Toloza S; Fernández M; Roseman JM; Bastian HM; Cepeda EJ; González EB; Baethge BA; Fessler BJ; Vilá LM; Reveille JD; Alarcón GS;
Ann Rheum Dis; 2006 Jun; 65(6):785-90. PubMed ID: 16269429
[TBL] [Abstract][Full Text] [Related]
18. Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus.
Shah M; Chaudhari S; McLaughlin TP; Kan HJ; Bechtel B; Dennis GJ; Molta CT
Clin Ther; 2013 Apr; 35(4):486-97. PubMed ID: 23587268
[TBL] [Abstract][Full Text] [Related]
19. Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy.
Abeles M; Urman JD; Rothfield NF
Arch Intern Med; 1978 May; 138(5):750-4. PubMed ID: 646538
[TBL] [Abstract][Full Text] [Related]
20. High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review.
Mont MA; Pivec R; Banerjee S; Issa K; Elmallah RK; Jones LC
J Arthroplasty; 2015 Sep; 30(9):1506-1512.e5. PubMed ID: 25900167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
